The stock closed at ₹14.43 on June 01, 2026, down 3.67% from the previous session, reflecting continued investor scepticism despite the quarterly improvement. With a proprietary Mojo Score of just 23 out of 100 and a "Strong Sell" rating, the company faces an uphill battle to restore confidence in its operational turnaround and financial sustainability.
The company's Q4 FY26 performance, whilst showing sequential improvement, reveals deeper structural issues. Net sales of ₹2.28 crores represented a robust 49.02% quarter-on-quarter increase and a 39.02% year-on-year improvement, yet the company struggled to translate this top-line growth into meaningful profitability. Operating profit before depreciation, interest, tax, and other income remained negative at ₹0.04 crores, highlighting persistent cost management challenges.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | PAT Margin |
|---|---|---|---|---|
| Mar'26 | 2.28 | +49.02% | 0.03 | 1.32% |
| Dec'25 | 1.53 | +4.79% | -0.08 | -5.23% |
| Sep'25 | 1.46 | -21.08% | -0.16 | -10.96% |
| Jun'25 | 1.85 | +12.80% | 0.03 | 1.62% |
| Mar'25 | 1.64 | -36.92% | 0.06 | 3.66% |
| Dec'24 | 2.60 | +9.24% | 0.06 | 2.31% |
| Sep'24 | 2.38 | — | -0.05 | -2.10% |
Financial Performance: Revenue Volatility Masks Profitability Crisis
Lime Chemicals' Q4 FY26 financial performance presents a picture of acute operational distress masked by sporadic revenue spikes. Net sales of ₹2.28 crores in Q4 FY26 marked a significant 49.02% sequential increase from Q3 FY26's ₹1.53 crores, and a 39.02% year-on-year improvement over Q4 FY25's ₹1.64 crores. However, this top-line growth failed to translate into sustainable profitability, with the company barely eking out a net profit of ₹0.03 crores, identical to the profit posted in Q4 FY25.
The quarter's operating margin excluding other income stood at a deeply negative 1.75%, a marginal improvement from Q3 FY26's -5.88% but still firmly in loss-making territory. The company's reliance on other income of ₹0.12 crores—representing a substantial portion of total income—proved critical in pushing the company into marginal profitability. Without this non-operating cushion, the company would have posted yet another quarterly loss.
On an annual basis, FY26's performance (based on available nine-month data through Q3 FY26) showed net sales of ₹5.27 crores, representing a concerning 20.39% decline from the comparable nine-month period in FY25. This deterioration in full-year revenue trajectory, despite Q4's strong showing, underscores the company's inability to sustain consistent sales momentum across quarters.
The company's cost structure remains a critical concern. Employee costs of ₹0.20 crores in Q4 FY26 represented 8.77% of net sales, up from 7.32% in the previous quarter, indicating rising personnel expenses relative to revenue. Interest costs, whilst minimal at ₹0.02 crores in Q4 FY26, highlight the company's limited access to debt financing—a double-edged sword that constrains both financial risk and growth capital availability.
Operational Challenges: Structural Weaknesses Remain Unaddressed
Lime Chemicals' operational metrics paint a sobering picture of a company struggling with fundamental business viability. The company's five-year sales growth stands at a dismal -23.06%, reflecting sustained revenue contraction over the medium term. More alarmingly, five-year EBIT growth has collapsed at -187.74%, indicating a complete erosion of operating profitability over time.
Return on capital employed (ROCE) averaged -27.85% over recent years, with the latest reading at -9.23%—both figures indicating value destruction rather than creation. The company's return on equity (ROE) averaged 0.0%, essentially signalling that shareholder capital has generated no meaningful returns. The latest ROE of -8.33% further underscores the company's inability to generate positive returns for equity holders.
The balance sheet reveals a company operating on a financial knife-edge. Shareholder funds stood at just ₹1.94 crores as of March 2025, with negative reserves and surplus of ₹4.56 crores partially offset by share capital of ₹6.50 crores. This precarious equity base, combined with current liabilities of ₹7.80 crores against current assets of ₹3.58 crores, points to acute working capital stress and potential liquidity challenges.
Critical Operational Red Flags
Negative Operating Margins: The company has consistently operated with negative EBITDA margins excluding other income, indicating that core business operations are loss-making. The -1.75% operating margin in Q4 FY26, whilst an improvement, remains deeply concerning.
Working Capital Strain: With current liabilities exceeding current assets by ₹4.22 crores, the company faces significant short-term liquidity pressures that could constrain operational flexibility.
Eroding Equity Base: Cumulative losses have eroded reserves to -₹4.56 crores, leaving shareholder funds at a meagre ₹1.94 crores—barely sufficient to support ongoing operations.
Industry Context: Struggling in a Competitive Commodity Market
Lime Chemicals operates in the highly competitive commodity chemicals sector, specifically in the manufacture of calcium carbonate for diverse applications including toothpaste, pharmaceuticals, PVC products, rubber, plastics, and paints. This sector is characterised by intense price competition, commodity-like pricing dynamics, and thin margins that reward scale and operational efficiency—attributes the company currently lacks.
The company's micro-cap status (₹9.39 crores market capitalisation) places it at a severe disadvantage relative to larger, better-capitalised competitors who can achieve economies of scale, invest in technology upgrades, and weather cyclical downturns. With just 65.05 crore shares outstanding and a face value of ₹10 per share, the company's limited equity base constrains its ability to raise growth capital or make strategic investments.
The broader commodity chemicals sector in India has faced headwinds from volatile raw material prices, subdued demand from key end-user industries, and increasing competition from imports. Lime Chemicals' 17.07% stock price decline over the past year, compared to the sector's 4.36% positive return, highlights its significant underperformance and investor concerns about its competitive positioning.
| Company | P/E (TTM) | P/BV | Debt/Equity | Market Cap |
|---|---|---|---|---|
| Lime Chemicals | NA (Loss Making) | 5.41x | 2.67 | ₹9.39 Cr |
| Tulasee Bio-Ethanol | 37.00x | 17.76x | -0.01 | — |
| Sreechem Resins | NA (Loss Making) | 1.01x | 0.15 | — |
| Emmessar Biotech | 30.12x | 1.59x | -0.90 | — |
| Link Pharma Chem | 155.42x | 0.95x | 0.50 | — |
| Kuwer Industries | 128.98x | 0.65x | 2.02 | — |
Valuation Analysis: Risky Premium Despite Operational Distress
Lime Chemicals' valuation metrics present a paradoxical picture of a loss-making company trading at elevated multiples relative to its asset base and operational performance. The stock's price-to-book value ratio of 5.41x appears extraordinarily high for a company with negative operating margins and minimal profitability. This valuation premium—trading at more than five times book value—seems entirely unjustified given the company's financial distress and uncertain turnaround prospects.
The company's enterprise value to EBITDA multiple of -14.55x and EV to EBIT of -14.55x reflect the negative earnings reality, making traditional valuation metrics largely meaningless. With an EV to sales ratio of 2.25x, the company is valued at more than double its annual revenue—a multiple typically reserved for high-growth, high-margin businesses, which Lime Chemicals decidedly is not.
The stock's 52-week range of ₹11.15 to ₹19.73 shows significant volatility, with the current price of ₹14.43 sitting 26.86% below the 52-week high and 29.42% above the 52-week low. This positioning suggests the stock has already corrected substantially from recent peaks, yet remains vulnerable to further downside given the company's deteriorating fundamentals and lack of visible catalysts for improvement.
Valuation Dashboard
P/E Ratio (TTM): NA (Loss Making) | P/BV Ratio: 5.41x | EV/Sales: 2.25x | Dividend Yield: NA
Overall Assessment: Risky valuation with elevated multiples unsupported by operational performance or growth visibility.
Shareholding: Promoter Commitment Stable, Institutional Exit Signals Concern
Lime Chemicals' shareholding pattern reveals a stable promoter base but concerning institutional exit trends. Promoter holding has remained constant at 29.27% over the past five quarters, indicating neither increased commitment through additional purchases nor dilution through stake sales. This stability, whilst providing some governance continuity, also suggests promoters may lack the financial capacity or conviction to increase their stake during this period of operational distress.
More troubling is the complete exit of foreign institutional investors (FIIs) in Q4 FY26, with FII holding dropping to 0.00% from 2.35% in Q3 FY26. This 2.35 percentage point reduction represents a clear vote of no confidence from sophisticated international investors who have chosen to completely divest their positions. Mutual fund holdings remain minimal at 0.05%, with just five mutual fund schemes holding positions—indicating negligible institutional interest.
| Quarter | Promoter | FII | Mutual Fund | Non-Institutional |
|---|---|---|---|---|
| Mar'26 | 29.27% | 0.00% | 0.05% | 70.68% |
| Dec'25 | 29.27% | 2.35% | 0.05% | 68.33% |
| Sep'25 | 29.27% | 2.35% | 0.05% | 68.33% |
| Jun'25 | 29.27% | 2.35% | 0.05% | 68.33% |
| Mar'25 | 29.27% | 3.07% | 0.05% | 67.60% |
Non-institutional holdings increased to 70.68% in Q4 FY26 from 68.33% in Q3 FY26, absorbing the FII exit. This shift towards retail and non-institutional investors typically indicates lower quality shareholding, with potentially less patient capital and higher susceptibility to sentiment-driven selling pressure.
Stock Performance: Persistent Underperformance Across All Timeframes
Lime Chemicals' stock price performance has been abysmal across virtually every meaningful timeframe, consistently underperforming both the broader market and its sector peers. The stock has declined 17.07% over the past year, significantly worse than the Sensex's 8.78% decline, resulting in negative alpha of 8.29 percentage points. This underperformance reflects investor recognition of the company's deteriorating fundamentals and limited turnaround prospects.
The medium to long-term picture is even more concerning. Over three years, the stock has plummeted 35.44% whilst the Sensex gained 19.01%—a staggering 54.45 percentage point underperformance. The five-year return of -46.26% against the Sensex's 43.06% gain represents an 89.32 percentage point deficit, highlighting the company's chronic value destruction over an extended period.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -8.38% | -2.86% | -5.52% |
| 1 Month | 0.35% | -3.40% | +3.75% |
| 3 Month | -0.69% | -8.60% | +7.91% |
| 6 Month | 6.89% | -13.25% | +20.14% |
| 1 Year | -17.07% | -8.78% | -8.29% |
| 3 Years | -35.44% | 19.01% | -54.45% |
| 5 Years | -46.26% | 43.06% | -89.32% |
The stock's high beta of 1.50 indicates it is significantly more volatile than the broader market, amplifying both gains and losses. However, given the predominantly negative returns, this high beta has primarily magnified downside risk rather than upside potential. The stock's risk-adjusted return of -0.22 over the past year, compared to the Sensex's -0.67, offers little consolation given the absolute wealth destruction.
Technical indicators paint a mixed picture, with the stock currently in a "sideways" trend as of May 25, 2026. The stock trades below all major moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating weak technical momentum and lack of buying support at current levels.
Investment Thesis: Multiple Red Flags Overwhelm Limited Positives
The investment case for Lime Chemicals is fundamentally challenged by structural operational weaknesses, persistent losses, and a deteriorating financial position that offers little visibility of sustainable turnaround. The company's Mojo Score of 23 out of 100 and "Strong Sell" rating reflect the overwhelming weight of negative factors that far outweigh any potential positives.
Key Strengths & Risk Factors
Key Strengths
- Sequential Improvement: Q4 FY26 showed positive net profit of ₹0.03 crores versus ₹0.08 crore loss in Q3 FY26
- Revenue Growth: Q4 net sales grew 49.02% QoQ and 39.02% YoY to ₹2.28 crores
- No Promoter Pledging: Zero pledged shares indicates no immediate governance concerns
- Stable Promoter Holding: Consistent 29.27% promoter stake over past five quarters
- Established Presence: Company incorporated in 1970 with long operating history in calcium carbonate manufacturing
Key Concerns
- Negative Operating Margins: -1.75% operating margin in Q4 FY26; core business remains loss-making
- Severe Working Capital Stress: Current liabilities of ₹7.80 crores exceed current assets of ₹3.58 crores by ₹4.22 crores
- Eroded Equity Base: Negative reserves of ₹4.56 crores leave shareholder funds at just ₹1.94 crores
- Persistent Value Destruction: Five-year ROCE of -27.85% and average ROE of 0.0%
- Institutional Exit: FII holdings dropped to 0.00% from 2.35%, signalling loss of confidence
- Revenue Volatility: Nine-month FY26 sales declined 20.39% YoY despite Q4 spike
- Chronic Underperformance: Stock down 46.26% over five years vs Sensex gain of 43.06%
Outlook: What to Watch
Positive Catalysts
- Sustained quarterly profitability for at least three consecutive quarters
- Positive operating margins (excluding other income) indicating core business viability
- Improvement in working capital position with current ratio above 1.0x
- Return of institutional investor interest with FII/MF stake increases
- Consistent revenue growth without quarter-to-quarter volatility
Red Flags
- Return to quarterly losses in Q1 FY27 or subsequent quarters
- Further deterioration in operating margins below -5%
- Working capital crisis leading to inability to meet short-term obligations
- Additional erosion of shareholder funds below ₹1.50 crores
- Promoter stake reduction signalling loss of confidence
The Verdict: High-Risk Turnaround Story with Limited Visibility
Score: 23/100
For Fresh Investors: Avoid initiating positions. The company's negative operating margins, eroded equity base, and persistent value destruction make it unsuitable for fresh capital deployment. The Q4 profit appears more tactical than sustainable, and structural challenges remain unaddressed.
For Existing Holders: Consider exiting on any price strength. The FII exit, consistently negative operating performance, and working capital stress present significant downside risks. The stock's elevated P/BV ratio of 5.41x is unjustified given operational realities.
Fair Value Estimate: Given negative operating margins and structural challenges, the stock appears overvalued even at current levels. A fair value closer to book value (₹2.99) would be more appropriate, suggesting 79% downside risk from current price of ₹14.43.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Investments in micro-cap stocks carry significantly higher risks including liquidity constraints, operational uncertainties, and potential total loss of capital.
